ontario regulation 645/05

made under the

Ontario drug benefit act

Made: December 7, 2005
Filed: December 9, 2005
Published on e-Laws: December 12, 2005
Printed in The Ontario Gazette: December 24, 2005


Amending O. Reg. 201/96

(General)

1. (1) The definition of “Formulary” in subsection 1 (1) of Ontario Regulation 201/96 is revoked and the following substituted:

“Formulary” means the Ministry of Health and Long-Term Care publication titled “Drug Benefit Formulary/Comparative Drug Index” (No. 39) dated September 27, 2005, and includes the following amendments to the publication,

1. Amendments dated January 12, 2006;

(2) Section 1 of the Regulation is amended by adding the following subsection:

(1.1) For the purposes of this Regulation, items 17 and 18 of Part III of the Formulary shall be read as follows:

VORICONAZOLE


17


50mg Tab


 


 


11.8800




 


02256460


Vfend


PFI


11.8800




18


200mg Tab


 


 


47.5000




 


02256479


Vfend


PFI


47.5000




 


Reason for Use Code


Clinical Criteria




 


399


Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole. The first prescription must be written by a physician based at the hospital where the patient was hospitalized. Note: Limited to 3 months of reimbursement.  LU Authorization Period: 1 year.




2. Clause 12 (1) (b) of the Regulation is amended by striking out “Canadian Coordinating Office of Health Technology Assessment” wherever it appears and substituting in each case “Canadian Coordinating Office for Health Technology Assessment.”

3. This Regulation comes into force on January 12, 2006.